Funding for this research was provided by:
Health Services and Delivery Research Programme (HS&DR - 14/21/52)
National Institute for Health Research (NF-SI-0616-10040)
Received: 13 August 2018
Accepted: 20 June 2019
First Online: 9 July 2019
Ethics approval and consent to participate
: This study received ethical approval from the Health Research Authority (HRA) approval (HRA-IRAS reference 159209) and the University of Exeter Medical School Ethics Committee (REC Application Number: 15/07/070). Both regarded this work as not requiring informed consent, as consent was implied by the participants choice to respond to the survey.
: Not applicable.
: Kings College London research support account for Professor Philip Asherson received honoraria for consultancy to Shire, Flynn-Pharma, Eli-Lilly, Novartis, Lundbeck and Medice; educational/research awards from Shire, Lilly, Novartis, Flynn Pharma, Vifor Pharma, GW Pharma and QbTech; speaker at sponsored events for Shire, Lilly, Novartis, Medice and Flynn Pharma.No other authors have any competing interests to declare.